WO2023150375A3 - Methods and compositions for treating covid infections - Google Patents

Methods and compositions for treating covid infections Download PDF

Info

Publication number
WO2023150375A3
WO2023150375A3 PCT/US2023/012488 US2023012488W WO2023150375A3 WO 2023150375 A3 WO2023150375 A3 WO 2023150375A3 US 2023012488 W US2023012488 W US 2023012488W WO 2023150375 A3 WO2023150375 A3 WO 2023150375A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
methods
infections
compositions
treating covid
Prior art date
Application number
PCT/US2023/012488
Other languages
French (fr)
Other versions
WO2023150375A2 (en
Inventor
Bradley Pentelute
Barbara L. HIBNER
Original Assignee
Decoy Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decoy Therapeutics Inc. filed Critical Decoy Therapeutics Inc.
Publication of WO2023150375A2 publication Critical patent/WO2023150375A2/en
Publication of WO2023150375A3 publication Critical patent/WO2023150375A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention provides a compound having the formula: (Peptide-Linker)n-B-Hydrophobic Moiety wherein each Peptide is independently a HRC Peptide or a targeting peptide, provided that at least one peptide is a HRC Peptide, each Linker is independently a bivalent linking moiety, B is a multivalent moiety comprising cysteine, X, and optionally Y, and/or optionally Z, wherein X, Y and Z are defined herein, and n is an integer selected from 1, 2, 3 or more and methods of treating or preventing a viral infection in a subject in need thereof using the same.
PCT/US2023/012488 2022-02-07 2023-02-07 Methods and compositions for treating covid infections WO2023150375A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263307371P 2022-02-07 2022-02-07
US63/307,371 2022-02-07
US202217870158A 2022-07-21 2022-07-21
US202217870174A 2022-07-21 2022-07-21
US17/870,158 2022-07-21
US17/870,174 2022-07-21

Publications (2)

Publication Number Publication Date
WO2023150375A2 WO2023150375A2 (en) 2023-08-10
WO2023150375A3 true WO2023150375A3 (en) 2023-10-19

Family

ID=87552901

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/012488 WO2023150375A2 (en) 2022-02-07 2023-02-07 Methods and compositions for treating covid infections

Country Status (1)

Country Link
WO (1) WO2023150375A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021046398A2 (en) * 2019-09-04 2021-03-11 The Trustees Of Columbia University In The City Of New York Combination antiviral therapy for measles
WO2021178971A1 (en) * 2020-03-06 2021-09-10 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccines against sars-cov-2 and other coronaviruses
WO2021195401A1 (en) * 2020-03-25 2021-09-30 Biohaven Therapeutics Ltd. Technologies for preventing or treating infections
WO2021207517A2 (en) * 2020-04-10 2021-10-14 Sapience Therapeutics, Inc. Modified hr2 peptide inhibitors of coronavirus fusion
US11180534B1 (en) * 2021-06-04 2021-11-23 Morehouse School Of Medicine Compositions and methods for treating SARS-CoV-2 infections

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021046398A2 (en) * 2019-09-04 2021-03-11 The Trustees Of Columbia University In The City Of New York Combination antiviral therapy for measles
WO2021178971A1 (en) * 2020-03-06 2021-09-10 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccines against sars-cov-2 and other coronaviruses
WO2021195401A1 (en) * 2020-03-25 2021-09-30 Biohaven Therapeutics Ltd. Technologies for preventing or treating infections
WO2021207517A2 (en) * 2020-04-10 2021-10-14 Sapience Therapeutics, Inc. Modified hr2 peptide inhibitors of coronavirus fusion
US11180534B1 (en) * 2021-06-04 2021-11-23 Morehouse School Of Medicine Compositions and methods for treating SARS-CoV-2 infections

Also Published As

Publication number Publication date
WO2023150375A2 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
HUP0002454A2 (en) Targeted therapeutic delivery of vitamin d compounds
CY1109497T1 (en) THIOPHENEI PRODUCTS AS ANTIBIOTIC FACTORS FOR FLAVIVIRUS INFECTION / INFECTION
TR200102128T2 (en) Ketolid antibiotics
IL172189A (en) Triheterocyclic compounds, compositions, methods for making and uses thereof
MX2007004783A (en) Inhibitors of hepatitis c virus protease, and compositions and treatments using the same.
TWI262805B (en) Pharmaceutical composition for treating or inhibiting colonic polyps
EA200201279A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL HEPATITIS C
CY1107626T1 (en) PYRAZOLI PRODUCTS FOR HIV TREATMENT
RU95106362A (en) Lipopeptide derivatives, process for preparation thereof, pharmaceutical composition containing said derivatives, and process for preparation of said composition
MX2022016405A (en) 1'-cyano nucleoside analogs and uses thereof.
ES2051641B1 (en) PROCEDURES FOR THE PREPARATION OF THIOUREA-DERIVED COMPOUNDS.
NO20033220L (en) Inhibitors of cruzipain and other cysteine proteases
EA202192669A1 (en) SOLID FORMS OF THE BETA-LACTAMASE INHIBITOR FOR ORAL DELIVERY AND THEIR USE
BR112023006761A2 (en) SHORT RING MODIFIED PROLINE PEPTIDE COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USE THEREOF
MX2023002233A (en) Phospholipid compounds and uses thereof.
WO2001055131A3 (en) Prodigiosin-derivatives as neoplastic and anti-viral agents
WO2023150375A3 (en) Methods and compositions for treating covid infections
DK1053012T3 (en) Pharmaceutical compositions comprising PEG asparaginase for the treatment of HIV infections
DK0723440T3 (en) Therapeutic delivery compositions and methods for using the same
BRPI0519752A2 (en) peptide compounds
UA97633C2 (en) Cyclic antimicrobial peptides
PH12021550323A1 (en) Dendrimer formulations
HK1068344A1 (en) Dimeric compounds and their use as anti-viral agents
WO2002010124A3 (en) Salt forms of an hiv protease inhibitor
MX2023001049A (en) Compositions and methods for treating viral infections.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23750271

Country of ref document: EP

Kind code of ref document: A2